Opinion: STAT+: China’s strict new supply chain regulations could create massive problems for Western biopharma companies

STAT PlusOpinionOpinions+ China’s strict new supply chain regulations could create massive problems for Western biopharma companies Just as it did with rare earth minerals, China is tightening control Manage alerts for this article Email this article Share this article By Dennis KwokMay 4, 2026 Kwok is a former member of the Hong Kong Legislative Council and is principal at Fountainhead Global Partners. A recently published paper delivers a finding that should be well known to every executive in Western pharma: China has gone from accounting for less than 8% of global clinical trials in 2010 to surpassing the United States in annual registered trial volume by 2020, reaching more than 5,000 trials per year in 2024. Eighty-eight percent of that growth, among private-sector sponsors, was driven by domestic Chinese firms, not multinationals relocating R&D. China is not just a manufacturing base for the West’s drug supply chain. It is now a peer competitor in drug innovation — and it intends to stay that way on its own terms.Advertisement Toward that end, on April 7, China’s State Council issued Decree No. 834, the Regulations on Industrial and Supply Chain Security, effective immediately, with no transition period. Its 18 articles give Beijing sweeping new powers to investigate and sanction any foreign company whose commercial decisions are deemed to harm China’s industrial chain security. China’s 15th five-year plan has explicitly designated biotechnology and pharmaceuticals as the centerpiece of its next phase of industrial development. Decree No. 834 is the legal infrastructure through which Beijing intends to protect and leverage that ambition. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Pharmaceuticals, Policy, STAT+ Submit a correction requestReprints Dennis Kwok Newsletter The smartest thinkers in life sciences on what's happening — and what's to come Recommended First Opinion May 4, 2026 Are blue zones real? Answering that question is harder than ever First Opinion Podcast May 2, 2026 What do medical students think about their education? Advertisement Letters to the editor May 2, 2026 STAT readers on MAHA activists, perimenopause, and diversity in medical school First Opinion May 1, 2026 America is worrying about fertility again. But it’s not really about families First Opinion May 1, 2026 The psychedelic revolution is leaving behind people of color Subscriber Picks